The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Asoprisnil is a selective progesterone receptor modulator with mixed progesterone agonist/antagonist activity which controls uterine bleeding via an endometrial effect. This study examined full-thickness endometrial, leiomyoma and myometrial morphology in hysterectomy specimens from patients with uterine leiomyomata, after treatment with asoprisnil for 3 months. METHODS: In this double-blind, randomized, placebo-controlled study, 33 subjects with uterine leiomyomata were randomized to receive asoprisnil 10, 25 mg or placebo for an average of 95 days prior to hysterectomy. Samples of endometrium, myometrium and leiomyoma tissue were subjected to systematic morphological assessment with quantification of mitotic activity. RESULTS: In patients treated with 10 or 25 mg asoprisnil, a unique pattern called 'non-physiologic secretory effect' was evident in endometrium, recognizable through partially developed secretory glandular appearances and stromal changes. Endometrial thickness was decreased, and there were low levels of mitotic activity in endometrial glands and stroma. Unusual thick-walled muscular arterioles and prominent aggregations of thin-walled vessels were present in endometrial stroma, but not in myometrium or non-endometrial vascular beds. Mitotic activity was decreased in leiomyomata. CONCLUSIONS: Asoprisnil induces unique morphological changes and is associated with low levels of glandular and stromal proliferation in endometrium, and in leiomyomata. These changes are likely to contribute to the amenorrhoea experienced after exposure to the medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chwalisz, K., Perez, M. C., DeManno, D., Winkel, C., Schubert, G., & Elger, W. (2005) · Endocrine Reviews · doi:10.1210/er.2005-0001 · Cited by 310
Cited by
Uterine fibroid management: From the present to the future
Donnez, J., & Dolmans, M.-M. (2016) · Human Reproduction Update · doi:10.1093/humupd/dmw023 · Cited by 780
Bulun, S. E. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1209993 · Cited by 703
Physiology of the Endometrium and Regulation of Menstruation
Critchley, H. O. D., Maybin, J. A., Armstrong, G. M., & Williams, A. R. W. (2020) · Physiological Reviews · doi:10.1152/physrev.00031.2019 · Cited by 536
Self-citationGlasier, A. F., Cameron, S. T., Fine, P. M., Logan, S. J., Casale, W., Van Horn, J., Sogor, L., Blithe, D. L., Scherrer, B., Mathe, H., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60101-8 · Cited by 526
Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer
Kim, J. J., Kurita, T., & Bulun, S. E. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1043 · Cited by 520
Uterine fibroids: current perspectives
Khan, A., Shehmar, M., & Gupta, J. (2014) · International Journal of Women's Health · doi:10.2147/ijwh.s51083 · Cited by 406
Progesterone Is Essential for Maintenance and Growth of Uterine Leiomyoma
Ishikawa, H., Ishi, K., Serna, V. A., Kakazu, R., Bulun, S. E., & Kurita, T. (2010) · Endocrinology · doi:10.1210/en.2009-1225 · Cited by 362
Role of nuclear progesterone receptor isoforms in uterine pathophysiology
Patel, B., Elguero, S., Thakore, S., Dahoud, W., Bedaiwy, M., & Mesiano, S. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmu056 · Cited by 353
Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics
Islam, M. S., Ciavattini, A., Petraglia, F., Castellucci, M., & Ciarmela, P. (2018) · Human Reproduction Update · doi:10.1093/humupd/dmx032 · Cited by 321
Selective Progesterone Receptor Modulators—Mechanisms and Therapeutic Utility
Islam, M. S., Afrin, S., Jones, S. I., & Segars, J. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa012 · Cited by 143
“Asoprisnil was under investigation by Schering AG (Wedding, Berlin, Germany) and TAP Pharmaceutical Products (Lake Forest, Illinois) but clinical development was discontinued in 2007 due to the observation of abnormal endometrial changes in patients (230).”
BackgroundMethodWilkens, J., Male, V., Ghazal, P., Forster, T., Gibson, D. A., Williams, A. R. W., Brito-Mutunayagam, S. L., Craigon, M., Lourenco, P., Cameron, I. T., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300958 · Cited by 101
Self-citationGonadotropin-releasing hormone antagonist (linzagolix): A new therapy for uterine adenomyosis
Donnez, O., & Donnez, J. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.04.017 · Cited by 58
Donnez, J., & Dolmans, M.-M. (2020) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2020.05.017 · Cited by 50
Metadata
- Authors
- Williams, A. R. W., Critchley, H. O. D., Osei, J., Ingamells, S., Cameron, I. T., Han, C., & Chwalisz, K.
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-03-05
- Volume
- 22
- Issue
- 6
- Pages
- 1696-1704
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W1984592479
- Cited by
- 122
- References
- 1
- FWCI
- 10.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.